- $2.32bn
- $1.65bn
- $650.35m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 55.3 | 104 | 244 | 419 | 650 |
Cost of Revenue | |||||
Gross Profit | 35.9 | 60.1 | 130 | 202 | 277 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 37.7 | 73.2 | 160 | 291 | 471 |
Operating Profit | 17.6 | 30.9 | 83.8 | 128 | 180 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 17.8 | 31.4 | 85.5 | 120 | 179 |
Provision for Income Taxes | |||||
Net Income After Taxes | 15.6 | 28.2 | 77.9 | 109 | 149 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 15.6 | 28.2 | 77.9 | 109 | 149 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 15.6 | 28.2 | 77.9 | 109 | 149 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.056 | 0.094 | 0.254 | 0.363 | 0.488 |
Dividends per Share |